文献速递乳腺乳腺X线

立体定向真空辅助活检用于不可触及乳腺病变的成本效益

Cost-effectiveness of stereotactic vacuum-assisted biopsy for nonpalpable breast lesions.
PubMed 文献 · Eur J Radiol · 2020-04-08

该回顾性研究纳入276例立体定向真空辅助活检(SVAB)和541例开放手术活检(OSB)记录,比较二者直接与间接成本。SVAB使每次诊断直接成本降低90.3美元(10.1%),间接成本降低560.2美元(96.0%),总资源利用节省43.9%。作者结论认为SVAB是不可触及乳腺病变的成本效益诊断选择,对BI-RADS 4A类和3类病变节省效果更大。

要点

  • SVAB较OSB每次诊断直接成本降低90.3美元(10.1%),间接成本降低560.2美元(96.0%)。
  • 综合考虑后续恶性手术费用,从医疗提供者角度,病变恶性可能性低于19%时SVAB具有成本效益。
  • 基于BI-RADS阳性预测值,SVAB更适合4A类和3类病变,医学与社会资源节省更大。

核心结论

  • SVAB是不可触及乳腺病变的成本效益诊断选择,对BI-RADS 4A类和3类病变节省效果更大。

研究设计与样本

  • 回顾性研究,经机构审查委员会批准,在医学中心回顾276例(33.8%)SVAB和541例(66.2%)OSB病历记录。
  • 直接成本包括患者自付和国家健康保险申报费用;间接成本用病假天数、平均工资和年龄调整就业率计算。
  • 进行单因素和双因素敏感性分析;病变分类依据BI-RADS第4版或第5版评估类别。

诊断标准与关键数值

  • 从医疗提供者角度,病变恶性可能性低于19%时SVAB具有成本效益。
  • 基于BI-RADS类别的阳性预测值,SVAB更适合4A类和3类病变。

临床应用与阅片要点

  • 作者结论认为SVAB是不可触及乳腺病变的成本效益诊断选择,对BI-RADS 4A类和3类病变节省效果更大。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: To examine the potential cost-savings of stereotactic vacuum-assisted biopsy (SVAB) over open surgical biopsy (OSB) in diagnosis of nonpalpable lesions on mammography and to estimate the cost-saving effect on lesions at different levels of malignant probability.

METHODS: This retrospective study was approved by our Institutional Review Board. We retrospectively reviewed 276 (33.8 %) SVAB and 541 (66.2 %) OSB medical records at a medical center. Direct costs included patients' self-paid and national health insurance claim charges. Indirect costs were calculated using sick days, average salary, and age-adjusted employment rate. One-way and two-way sensitivity analyses were conducted. Lesion classification was determined by the assessment categories of Breast Imaging Reporting and Data System (BI-RADS), 4th or 5th editions.

RESULTS: SVAB decreased the direct cost by $90.3 (10.1 %) per diagnosis. The indirect cost was decreased by $560.2 (96.0 %). Overall, SVAB saved 43.9 % of resource utilization for each biopsy. Taking the cost of the subsequent malignant surgery into account, from the healthcare providers' perspective, SVAB was cost-effective if a lesion had less than 19 % likelihood of malignancy. From the societal perspective, SVAB reduced productivity loss for all the lesions. Based on the positive predictive value of the BI-RADS categories, SVAB was more suitable for the lesions of category 4A and category 3, resulting in greater savings in both medical and societal resources.

CONCLUSIONS: SVAB is a cost-effective diagnostic option for nonpalpable breast lesions. The cost-saving effect is greater for the lesions of category 4A and category 3.

来源:Eur J Radiol,查看原文。版权归原作者所有。

引用

  1. Tsai HY, Huang ST, Chao MF, et al. Cost-effectiveness of stereotactic vacuum-assisted biopsy for nonpalpable breast lesions. Eur J Radiol. 2020. PMID: 32334370. doi:10.1016/j.ejrad.2020.108982

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。